Volume 133, Issue 2



January 10, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Rip1k-mediated necroptosis leads to MDS in mice. See the article by Wagner et al.

Increased Ripk1-mediated bone marrow necroptosis leads to myelodysplasia and bone marrow failure in mice
In a plenary paper, Wagner et al link Ripk1-induced bone marrow necroptosis to inflammatory cytokine release, which leads to bone marrow failure in a mouse model of myelodysplasia (MDS). They confirm excess necroptosis in human MDS bone marrow, suggesting that Ripk1 may be a therapeutic target for the disease.

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy
Kusumoto and colleagues report the incidence of hepatitis B virus (HBV) reactivation in patients receiving anti-CD20 immunotherapy and compare the outcome of prophylactic therapy to the outcome of HBV DNA monitoring with preemptive therapy when reactivation is detected.

Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?
In a Perspective, Sarraf Yazdy and colleagues reflect on the efficacy of single-agent targeted agents (TAs) and doublet and triplet TA therapy for the treatment of chronic lyphocytic leukemia (CLL), which is moving the disease toward therapy that is individualized, potentially curative, and chemofree.

How I treat Philadelphia chromosome–positive acute lymphoblastic leukemia
Through the discussion of 5 illustrative cases, Ravandi describes his approach to the treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia in the era of availability of a broad range of tyrosine kinase inhibitors.

IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies
Despite the established efficacy of proteasome inhibitors (PIs) in multiple myeloma and mantle cell lymphoma, acquired dose resistance and dose-limiting toxicity impair their long-term efficacy. Bergaggio and colleagues demonstrate that IDH2 inhibition sensitizes cells to PIs, offering the possibility of extended efficacy through combining IDH2 inhibitors with lower doses of PIs.

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.